Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Zagrodzky

Clinical Cardiac Electrophysiology Austin, TX Medical Doctor

NPI 1912982018 CMS profile 177246

4316 James Casey Bldg, C, Suite 201, Austin, TX 78745

Open in the dashboard

General payments

$960,858

1,208 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Zagrodzky of Austin, TX is reported in the CMS Open Payments database as having received $960,858 across 1,208 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $106,868 115
2024 General $396,135 151
2023 General $87,217 246
2022 General $103,078 200
2021 General $67,583 156
2020 General $110,625 140
2019 General $89,352 200

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Zagrodzky
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Jason Zagrodzky were reported at $106,868. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Jason Zagrodzky Clinical Cardiac Electrophysiology median Middle half National median
2019 $89,352 $2,361 $585–$8,260 $163
2020 $110,625 $993 $247–$4,351 $114
2021 $67,583 $1,185 $326–$4,739 $132
2022 $103,078 $2,073 $554–$6,789 $149
2023 $87,217 $2,568 $759–$8,159 $160
2024 $396,135 $2,557 $703–$7,403 $164
2025 $106,868 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Haemonetics Corporation $330,443 3 payments
  2. Medical Device Business Services, Inc. $285,501 162 payments
  3. Biosense Webster, Inc. $275,824 360 payments
  4. Sanofi-Aventis U.S. LLC $26,287 29 payments
  5. Abbott Laboratories $24,214 217 payments
  6. Janssen Pharmaceuticals, Inc $5,662 65 payments
  7. Medtronic, Inc. $3,224 81 payments
  8. Atricure, Inc. $2,219 29 payments
  9. Cardiva Medical, Inc. $1,983 12 payments
  10. Pfizer Inc. $1,657 148 payments
  11. Other $3,845 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $574,557 220 payments
  2. Acquisitions $307,644 1 payment
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $32,674 18 payments
  4. Food and Beverage $25,406 900 payments
  5. Travel and Lodging $18,042 66 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $2,500 1 payment
  7. Education $36 2 payments
Products named General payments · program years 2019–2025
  1. Carto 3 $385,695 262 payments
  2. Carto 3 System $166,874 86 payments
  3. MULTAQ Cardiology/Vascular Diseases $21,479 17 payments
  4. Perclose ProGlide suture mediated closure system $9,567 15 payments
  5. Omnilink Elite vascular stent system $6,200 2 payments
  6. XARELTO $5,662 65 payments
  7. Carto Smarttouch $4,793 33 payments
  8. MULTAQ Cardiology/Vascular Diseases $4,699 7 payments
  9. PERCLOSE PROGLIDE $3,438 4 payments
  10. ARCTIC FRONT ADVANCE $2,447 4 payments
  11. Other $21,927 869 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

1,301

Median for Clinical Cardiac Electrophysiology: 1,090

Drug cost

$528,241

Median for Clinical Cardiac Electrophysiology: $354,841

Branded share of claims

55.3%

Median for Clinical Cardiac Electrophysiology: 38.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 300 $281,585
Xarelto Rivaroxaban Brand 195 $173,281
Multaq Dronedarone Hcl Brand 60 $51,640
Propafenone Hcl Er Propafenone Hcl Brand 31 $4,510
Dabigatran Etexilate Dabigatran Etexilate Mesylate Brand 11 $4,317
Amiodarone Hcl Generic 59 $2,918
Metoprolol Succinate Generic 124 $2,089
Flecainide Acetate Generic 66 $2,045
Mexiletine Hcl Generic 23 $1,464
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 44 $884

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,573 Part D prescribers listed as Clinical Cardiac Electrophysiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 69 billing codes

Paid by Medicare

$460,280

Medicare's payments for the services billed

Medicare patients

802

Average age 76

Services billed

5,476

332 women, 470 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 75%
Ischemic heart disease 57%
Heart failure 46%
Arthritis 46%
Diabetes 31%
Chronic kidney disease 27%
Depression 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MULTAQ
$2,170 60 —
ELIQUIS
$240 300 —
XARELTO
$106 195 —
NURTEC ODT
$71 — —
PAXLOVID
$43 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

1,208 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record